The additional value of 18F-FDG PET/CT imaging in guiding the treatment strategy of non-tuberculous mycobacterial patients
Abstract Objectives Non-tuberculous mycobacteria (NTM) infection is an increasing health problem due to delaying an effective treatment. However, there are few data on 18F-FDG PET/CT for evaluating the status of NTM patients. The aim of this study was to investigate the potential value of 18F-FDG PE...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-03-01
|
| Series: | Respiratory Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12931-024-02757-7 |
| _version_ | 1797247050724671488 |
|---|---|
| author | Donghe Chen Yunbo Chen Shuye Yang Kanfeng Liu Zhen Wang Tingting Zhang Guolin Wang Kui Zhao Xinhui Su |
| author_facet | Donghe Chen Yunbo Chen Shuye Yang Kanfeng Liu Zhen Wang Tingting Zhang Guolin Wang Kui Zhao Xinhui Su |
| author_sort | Donghe Chen |
| collection | DOAJ |
| description | Abstract Objectives Non-tuberculous mycobacteria (NTM) infection is an increasing health problem due to delaying an effective treatment. However, there are few data on 18F-FDG PET/CT for evaluating the status of NTM patients. The aim of this study was to investigate the potential value of 18F-FDG PET/CT in guiding the treatment strategy of NTM patients. Methods We retrospectively analyzed the cases of 23 NTM patients who underwent 18F-FDG PET/CT. The clinical data, including immune status and severity of NTM pulmonary disease (NTM-PD), were reviewed. The metabolic parameters of 18F-FDG included maximum standardized uptake value (SUVmax), SUVmax of the most FDG-avid lesion (SUVTop), SUVTop/SUVmax of the liver (SURLiver), SUVTop/SUVmax of the blood (SURBlood), metabolic lesion volume (MLV), and total lesion glycolysis (TLG). The optimal cut-off values of these parameters were determined using receiver operating characteristic curves. Results There were 6 patients (26.09%) with localized pulmonary diseases and 17 patients (73.91%) with disseminated diseases. The NTM lesions had high or moderate 18F-FDG uptake (median SUVTop: 8.2 ± 5.7). As for immune status, the median SUVTop in immunocompromised and immunocompetent patients were 5.2 ± 2.5 and 10.0 ± 6.4, respectively, with a significant difference (P = 0.038). As for extent of lesion involvement, SURLiver and SURBlood in localized pulmonary and disseminated diseases were 1.9 ± 1.1 vs. 3.8 ± 1.6, and 2.7 ± 1.8 vs. 5.5 ± 2.6, respectively, with a significant difference (P = 0.016 and 0.026). Moreover, for disease severity, SUVmax of the lung lesion (SUVI−lung) and SUVmax of the marrow (SUVMarrow) in the severe group were 7.7 ± 4.3 and 4.4 ± 2.7, respectively, significantly higher than those in the non-severe group (4.4 ± 2.0 and 2.4 ± 0.8, respectively) (P = 0.027 and 0.036). The ROC curves showed that SUVTop, SURLiver, SURBlood, SUVI−lung, and SUVMarrow had a high sensitivity and specificity for the identification of immune status, lesion extent, and severity of disease in NTM patients. Conclusion 18F-FDG PET/CT is a useful tool in the diagnosis, evaluation of disease activity, immune status, and extent of lesion involvement in NTM patients, and can contribute to planning the appropriate treatment for NTM. |
| first_indexed | 2024-04-24T19:52:32Z |
| format | Article |
| id | doaj.art-2afe9bee3e4a442ab0df6b77f61fa804 |
| institution | Directory Open Access Journal |
| issn | 1465-993X |
| language | English |
| last_indexed | 2024-04-24T19:52:32Z |
| publishDate | 2024-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Respiratory Research |
| spelling | doaj.art-2afe9bee3e4a442ab0df6b77f61fa8042024-03-24T12:29:55ZengBMCRespiratory Research1465-993X2024-03-0125111310.1186/s12931-024-02757-7The additional value of 18F-FDG PET/CT imaging in guiding the treatment strategy of non-tuberculous mycobacterial patientsDonghe Chen0Yunbo Chen1Shuye Yang2Kanfeng Liu3Zhen Wang4Tingting Zhang5Guolin Wang6Kui Zhao7Xinhui Su8Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of MedicineState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of MedicineAbstract Objectives Non-tuberculous mycobacteria (NTM) infection is an increasing health problem due to delaying an effective treatment. However, there are few data on 18F-FDG PET/CT for evaluating the status of NTM patients. The aim of this study was to investigate the potential value of 18F-FDG PET/CT in guiding the treatment strategy of NTM patients. Methods We retrospectively analyzed the cases of 23 NTM patients who underwent 18F-FDG PET/CT. The clinical data, including immune status and severity of NTM pulmonary disease (NTM-PD), were reviewed. The metabolic parameters of 18F-FDG included maximum standardized uptake value (SUVmax), SUVmax of the most FDG-avid lesion (SUVTop), SUVTop/SUVmax of the liver (SURLiver), SUVTop/SUVmax of the blood (SURBlood), metabolic lesion volume (MLV), and total lesion glycolysis (TLG). The optimal cut-off values of these parameters were determined using receiver operating characteristic curves. Results There were 6 patients (26.09%) with localized pulmonary diseases and 17 patients (73.91%) with disseminated diseases. The NTM lesions had high or moderate 18F-FDG uptake (median SUVTop: 8.2 ± 5.7). As for immune status, the median SUVTop in immunocompromised and immunocompetent patients were 5.2 ± 2.5 and 10.0 ± 6.4, respectively, with a significant difference (P = 0.038). As for extent of lesion involvement, SURLiver and SURBlood in localized pulmonary and disseminated diseases were 1.9 ± 1.1 vs. 3.8 ± 1.6, and 2.7 ± 1.8 vs. 5.5 ± 2.6, respectively, with a significant difference (P = 0.016 and 0.026). Moreover, for disease severity, SUVmax of the lung lesion (SUVI−lung) and SUVmax of the marrow (SUVMarrow) in the severe group were 7.7 ± 4.3 and 4.4 ± 2.7, respectively, significantly higher than those in the non-severe group (4.4 ± 2.0 and 2.4 ± 0.8, respectively) (P = 0.027 and 0.036). The ROC curves showed that SUVTop, SURLiver, SURBlood, SUVI−lung, and SUVMarrow had a high sensitivity and specificity for the identification of immune status, lesion extent, and severity of disease in NTM patients. Conclusion 18F-FDG PET/CT is a useful tool in the diagnosis, evaluation of disease activity, immune status, and extent of lesion involvement in NTM patients, and can contribute to planning the appropriate treatment for NTM.https://doi.org/10.1186/s12931-024-02757-7Non-tuberculous mycobacteriaNTM-PDDisseminated NTM infection PET/CT18F-FDG |
| spellingShingle | Donghe Chen Yunbo Chen Shuye Yang Kanfeng Liu Zhen Wang Tingting Zhang Guolin Wang Kui Zhao Xinhui Su The additional value of 18F-FDG PET/CT imaging in guiding the treatment strategy of non-tuberculous mycobacterial patients Respiratory Research Non-tuberculous mycobacteria NTM-PD Disseminated NTM infection PET/CT 18F-FDG |
| title | The additional value of 18F-FDG PET/CT imaging in guiding the treatment strategy of non-tuberculous mycobacterial patients |
| title_full | The additional value of 18F-FDG PET/CT imaging in guiding the treatment strategy of non-tuberculous mycobacterial patients |
| title_fullStr | The additional value of 18F-FDG PET/CT imaging in guiding the treatment strategy of non-tuberculous mycobacterial patients |
| title_full_unstemmed | The additional value of 18F-FDG PET/CT imaging in guiding the treatment strategy of non-tuberculous mycobacterial patients |
| title_short | The additional value of 18F-FDG PET/CT imaging in guiding the treatment strategy of non-tuberculous mycobacterial patients |
| title_sort | additional value of 18f fdg pet ct imaging in guiding the treatment strategy of non tuberculous mycobacterial patients |
| topic | Non-tuberculous mycobacteria NTM-PD Disseminated NTM infection PET/CT 18F-FDG |
| url | https://doi.org/10.1186/s12931-024-02757-7 |
| work_keys_str_mv | AT donghechen theadditionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT yunbochen theadditionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT shuyeyang theadditionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT kanfengliu theadditionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT zhenwang theadditionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT tingtingzhang theadditionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT guolinwang theadditionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT kuizhao theadditionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT xinhuisu theadditionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT donghechen additionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT yunbochen additionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT shuyeyang additionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT kanfengliu additionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT zhenwang additionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT tingtingzhang additionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT guolinwang additionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT kuizhao additionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients AT xinhuisu additionalvalueof18ffdgpetctimaginginguidingthetreatmentstrategyofnontuberculousmycobacterialpatients |